Clinical Trial Update: Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating aflibercept in combination with docetaxel for metastatic castration-resistant prostate cancer has completed with results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Taxotere (docetaxel)
• Zaltrap (ramucirumab)

Snippet

Sponsor: Sanofi | Conditions: Prostatic Neoplasms, Neoplasm Metastasis | Phase 3 | Status: COMPLETED | Results posted: 2013-10-10